Evidence map›Paper›PMID 30088346›Full record

ReviewESC heart failure2018

Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial.

Cristiane C K Mayerhofer, Ayodeji O Awoyemi, Samuel D Moscavitch, Knut Tore Lappegård, Johannes R Hov, Pål Aukrust, Anders Hovland, Andrea Lorenzo, Sigrun Halvorsen, Ingebjørg Seljeflot and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Cristiane C K MayerhoferDepartment of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Ayodeji O AwoyemiInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Samuel D MoscavitchLaboratory of Immunopharmacology, Oswaldo Cruz Institute, Rio de Janeiro, Brazil.
Knut Tore LappegårdDivision of Internal Medicine, Nordlandssykehuset, Bodø, Norway.
Johannes R HovResearch Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Anders HovlandDivision of Internal Medicine, Nordlandssykehuset, Bodø, Norway.
Andrea LorenzoInstituto Nacional de Cardiologia, Rio de Janeiro, Brazil.
Sigrun HalvorsenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Ingebjørg SeljeflotInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Lars GullestadDepartment of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Marius TrøseidResearch Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Kaspar BrochDepartment of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NOFundação Oswaldo Cruz · BRInstitute of Clinical Research · USInstituto Nacional de Cardiologia · BRNordland Hospital Trust · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHeart failure (HF) is a multifactorial disease. Current treatments target only a fraction of the putative pathophysiological pathways. In patients with HF, reduced cardiac output and congestion cause increased gut wall permeability. It has been suggested that leakage of microbial products is detrimental to the heart, at least partly through activation of systemic inflammatory pathways, which again could promote gut leakage. Whether manipulating the gut microbiota can improve cardiac function in patients with HF remains unknown. We aim to evaluate the effect of drugs targeting the gut microbiota on left ventricular function, quality of life, and functional capacity, as well as on markers of gut leakage and inflammation, in stable patients with HF with reduced ejection fraction. METHODS AND

resultsGutHeart is a randomized, open-label, controlled trial. Four centres will randomize 150 patients with stable HF and a left ventricular ejection fraction <40% to receive the antibiotic rifaximin, the probiotic yeast Saccharomyces boulardii (ATCC 74012), or no treatment (control) in a 1:1:1 fashion. Treatment will last for 3 months. The primary endpoint is baseline-adjusted left ventricular ejection fraction as measured by echocardiography after 3 months. A further follow-up 6 months after randomization will be undertaken.

conclusionsThis trial is likely to give new insights into important disease processes involving the gut microbiota in HF patients, hereby leading to new potential therapeutic strategies to prevent and down-regulate the inflammation seen in these patients.

Indexed as

Gastrointestinal MicrobiomeSaccharomyces boulardiiClinical Trials, Phase II as TopicHeart FailureHumansRandomized Controlled Trials as TopicStroke VolumeVentricular Function, LeftGut microbiotaHeart failureMicrobial translocationRandomized controlled trialRemodellingStudy design

Identifiers

PMID30088346
PMCPMC6165929
OpenAlexW2887974923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.